Biotech RadarJobs updated

COMPANY

Scynexis, Inc.

HQ: Jersey City, NJ source · scynexis.com ↗ · Mid-Atlantic

Clinical Phase 3

Also known as Scynexis · 23 sources

SCYNEXIS is advancing a portfolio of clinical-stage assets targeting the underlying biology of severe rare diseases. Scynexis is expanding its pipeline in severe rare diseases with high unmet medical need. From company website Source · Source · checked 2026-10-19

Sources for this description (2)
  • SCYNEXIS is advancing a portfolio of clinical-stage assets targeting the underlying biology of severe rare diseases.
    • “At SCYNEXIS, we are focused on advancing a portfolio of highly differentiated, clinical‑stage assets targeting the underlying biology of severe rare diseases.” https://www.scynexis.com/about/ (2026-10-19)
  • Scynexis is expanding its pipeline in severe rare diseases with high unmet medical need.

Therapeutic area: rare diseases

Keywords: autosomal dominant polycystic kidney disease Invasive Candidiasis Candidemia Vulvovaginal Candidiasis Candida Vulvovaginitis Invasive Pulmonary Aspergillosis Recurrent Vulvovaginal Candidiasis Candida Infection Vaginal Candidiasis Mucocutaneous Candidiasis Coccidioidomycosis Histoplasmosis Blastomycosis Chronic Pulmonary Aspergillosis Allergic Bronchopulmonary Aspergillosis Other Emerging Fungi Mycoses Fungal Disease Fungal Infection Hepatitis C Infection Chronic Hepatitis C SCY-078 Ibrexafungerp SCY-635

Location: Jersey City, NJ · source · Oct 15, 2026

Profile checked Oct 10, 2026

$40.0MRaised (2 yrs)18Trials (company is sponsor)2NIH grants

Timeline

  1. Grant Government contract: $214M (up to, as announced), announced Sep 28, 2026. Source: SEC filing. source ↗
  2. Raise Private placement: $40M (total, as published), announced Mar 31, 2026. Source: SEC filing. source ↗
  3. Partnership Partnership / licensing announced Nov 17, 2025. Source: company release on GlobeNewswire. source ↗
  4. Trial start Phase 1: Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp source ↗
  5. Trial start Phase 1: ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects source ↗
  6. Trial start 3: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole source ↗
  7. Trial start Phase 3: Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis source ↗
  8. Trial start Phase 1: ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects source ↗
  9. Trial start Phase 1: Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects source ↗
  10. Trial start 3: Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) source ↗
  11. Trial start Phase 1: Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects source ↗
  12. Trial start Phase 3: Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis source ↗
  13. Trial start Phase 2: Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis source ↗
  14. Trial start Phase 3: Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303) source ↗
  15. Trial start Phase 3: Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) source ↗
  16. Trial start Phase 2: Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis source ↗
  17. Trial start Phase 3: Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment source ↗
  18. Trial start Phase 2: Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis source ↗
  19. Trial start Phase 2: Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis source ↗
  20. Trial start Phase 2: Study of SCY-635, Pegasys and Copegus in Hepatitis C source ↗
  21. Trial start Phase 1: Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients source ↗

Funding

Raised: $40.0M. Last 2 years.

Clinical trials (lead sponsor) 18

RecordTitlePhaseStatusStartPrimary completion
NCT05178862A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole3TerminatedAug 3, 2022Nov 7, 2025 (actual)
NCT06954493Pharmacokinetic Study in Healthy Lactating Women Exposed to IbrexafungerpPhase 1CompletedJul 12, 2023Nov 1, 2023 (actual)
NCT03059992Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal TreatmentPhase 3CompletedApr 1, 2017Aug 25, 2023 (actual)
NCT03672292Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary AspergillosisPhase 2TerminatedJan 22, 2019Mar 27, 2023 (actual)
NCT05399641Ibrexafungerp for the Treatment of Complicated Vulvovaginal CandidiasisPhase 3CompletedMay 1, 2022May 16, 2023 (actual)
NCT03363841Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)Phase 3CompletedNov 15, 2017Apr 14, 2023 (actual)
NCT02244606Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive CandidiasisPhase 2Completed2014-092016-06 (actual)
NCT05668429ADME Study of [14^C]-Ibrexafungerp in Healthy Male SubjectsPhase 1CompletedDec 14, 2022Jan 28, 2023 (actual)
NCT04029116Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)3CompletedOct 21, 2019Sep 1, 2021 (actual)
NCT03734991Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)Phase 3CompletedJan 4, 2019Aug 21, 2019 (actual)
NCT03987620Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal CandidiasisPhase 3CompletedJun 7, 2019Mar 29, 2020 (actual)
NCT03253094Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal CandidiasisPhase 2CompletedAug 1, 2017May 4, 2018 (actual)
NCT04092751Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy SubjectsPhase 1CompletedNov 22, 2019Dec 20, 2019 (actual)
NCT04092725Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy SubjectsPhase 1CompletedSep 9, 2019Jan 3, 2020 (actual)
NCT04307082ADME Study of [14C]-Ibrexafungerp in Healthy Male SubjectsPhase 1CompletedDec 5, 2019May 29, 2020 (actual)
NCT02679456Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal CandidiasisPhase 2Completed2015-11Aug 5, 2016 (actual)
NCT01265511Study of SCY-635, Pegasys and Copegus in Hepatitis CPhase 2Completed2010-112011-10 (actual)
NCT01290965Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C PatientsPhase 1Completed2007-042008-12 (actual)

NIH awards 2

Annual award amounts. Total $448K.

Feedback